Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International journal for parasitology. Drugs and drug resistance Année : 2021

Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters

Résumé

Plasmodium vivax radical cure requires the administration of a blood schizonticide for killing blood-stage parasites and the addition of a drug able to kill hypnozoites, the dormant parasite stages residing in the liver of infected patients. All drugs used clinically for killing hypnozoites are 8-aminoquinolines and among them, primaquine has been at the forefront of P. vivax case management for decades. We discuss here the possible factors that could lead to the emergence and selection of P. vivax primaquine resistant parasites and emphasize on how a better understanding of the mechanisms underlying primaquine treatment and hypnozoite biology is needed to prevent this catastrophic scenario from happening.
Fichier principal
Vignette du fichier
Popovici_IJP2021review.pdf (892.98 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03494755 , version 1 (20-12-2021)

Licence

Paternité

Identifiants

Citer

Jean Popovici, Kieran Tebben, Benoit Witkowski, David Serre. Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters. International journal for parasitology. Drugs and drug resistance, 2021, 15, pp.36-42. ⟨10.1016/j.ijpddr.2020.12.004⟩. ⟨hal-03494755⟩

Collections

RIIP RIIP_CAMBODGE
15 Consultations
106 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More